homovanillic acid and g(m1) ganglioside

homovanillic acid has been researched along with g(m1) ganglioside in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (11.11)	18.7374
1990's	6 (66.67)	18.2507
2000's	2 (22.22)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
DiStefano, L; Pope, A; Schneider, JS; Simpson, K; Smith, MG; Taggart, J	1
Schneider, JS	1
de Montis, G; Rossetti, ZL; Stefanini, E; Vaccari, A	1
Albert, ML; Davoudi, H; Durso, R; Fazzini, E; Szabo, GK	1
Agnati, LF; Calza, L; Lombardi, G; Moroni, F; Savoini, G; Toffano, G	1
Ali, SF	1
DiStefano, L; Schneider, JS	1
Colvin, AE; Goettl, VM; Hadjiconstantinou, M; Neff, NH; Wemlinger, TA	1
Bråne, G; Karlsson, I; Lekman, A; Ramström, I; Svennerholm, L; Wikkelsö, C	1

Trials

1 trial(s) available for homovanillic acid and g(m1) ganglioside

Article	Year
Alzheimer disease - effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme. Dementia and geriatric cognitive disorders, 2002, Volume: 14, Issue:3 Topics: Aged; Alzheimer Disease; Cerebrovascular Circulation; Female; G(M1) Ganglioside; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Injections, Intraventricular; Male; Middle Aged; Neuropsychological Tests; Somatostatin; Treatment Outcome	2002

Article

Year

Alzheimer disease - effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme.

Dementia and geriatric cognitive disorders, 2002, Volume: 14, Issue:3

Topics: Aged; Alzheimer Disease; Cerebrovascular Circulation; Female; G(M1) Ganglioside; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Injections, Intraventricular; Male; Middle Aged; Neuropsychological Tests; Somatostatin; Treatment Outcome

2002

Other Studies

8 other study(ies) available for homovanillic acid and g(m1) ganglioside

Article	Year
Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science (New York, N.Y.), 1992, May-08, Volume: 256, Issue:5058 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; G(M1) Ganglioside; Homovanillic Acid; Immunohistochemistry; Macaca fascicularis; Motor Activity; Parkinson Disease, Secondary; Putamen; Reference Values; Saimiri; Tyrosine 3-Monooxygenase	1992
MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment. Journal of neuroscience research, 1992, Volume: 31, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cats; Caudate Nucleus; Dopamine; Female; G(M1) Ganglioside; Homovanillic Acid; Male; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary	1992
Dopaminergic dysfunction in neonatal hypothyroidism: differential effects of GM1 ganglioside. Neuropharmacology, 1990, Volume: 29, Issue:12 Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Animals, Newborn; Corpus Striatum; Dopamine; Female; G(M1) Ganglioside; Homovanillic Acid; Hypothyroidism; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Synaptosomes; Thyroid Gland; Tyramine	1990
GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice. Journal of the neurological sciences, 1990, Volume: 99, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Corpus Striatum; Dopamine; G(M1) Ganglioside; Homovanillic Acid; Male; Mice; Mice, Inbred Strains; Movement; Parkinson Disease; Parkinson Disease, Secondary	1990
GM1 ganglioside stimulates the regeneration of dopaminergic neurons in the central nervous system. Brain research, 1983, Feb-14, Volume: 261, Issue:1 Topics: Animals; Axons; Corpus Striatum; Dominance, Cerebral; Dose-Response Relationship, Drug; G(M1) Ganglioside; Gangliosides; Homovanillic Acid; Nerve Regeneration; Neurons; Rats; Rats, Inbred Strains; Receptors, Dopamine; Substantia Nigra; Tyrosine 3-Monooxygenase	1983
Lack of mitigation of methamphetamine-induced neurotoxicity by ganglioside GM1 or vitamin E. Annals of the New York Academy of Sciences, 1995, Sep-15, Volume: 765 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopamine; G(M1) Ganglioside; Homovanillic Acid; Hydroxyindoleacetic Acid; Methamphetamine; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Neurotoxins; Reactive Oxygen Species; Serotonin; Vitamin E	1995
Oral administration of semisynthetic sphingolipids promotes recovery of striatal dopamine concentrations in a murine model of parkinsonism. Neurology, 1994, Volume: 44, Issue:4 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Animals; Corpus Striatum; Dopamine; G(M1) Ganglioside; Homovanillic Acid; Male; Mice; Mice, Inbred C57BL; Osmolar Concentration; Parkinson Disease, Secondary; Sphingolipids; Sphingosine	1994
Motoric behavior in aged rats treated with GM1. Brain research, 2001, Jul-06, Volume: 906, Issue:1-2 Topics: Aging; Animals; Dopamine; G(M1) Ganglioside; Homovanillic Acid; Male; Motor Activity; Movement Disorders; Neostriatum; Neural Pathways; Neurons; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Substantia Nigra	2001